299 related articles for article (PubMed ID: 16960244)
1. Use of biologics in rheumatoid arthritis: where are we going?
Pucino F; Harbus PT; Goldbach-Mansky R
Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S19-41. PubMed ID: 16960244
[TBL] [Abstract][Full Text] [Related]
2. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
Furfaro N
J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
[TBL] [Abstract][Full Text] [Related]
4. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
Siddiqui MA
Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
[TBL] [Abstract][Full Text] [Related]
6. The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis.
Favalli EG; Pregnolato F; Biggioggero M; Meroni PL
Semin Arthritis Rheum; 2014 Jun; 43(6):730-7. PubMed ID: 24332807
[TBL] [Abstract][Full Text] [Related]
7. New therapies for treatment of rheumatoid arthritis.
Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
Gibbons LJ; Hyrich KL
BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
[TBL] [Abstract][Full Text] [Related]
9. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
Wollenhaupt J; Krüger K
Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
12. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis: Unraveling the conundrum.
Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
[TBL] [Abstract][Full Text] [Related]
14. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
Nurmohamed MT
Drugs; 2009 Oct; 69(15):2035-43. PubMed ID: 19791825
[TBL] [Abstract][Full Text] [Related]
15. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
16. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Levesque MC
BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
18. The use of biologic therapies in the treatment of rheumatoid arthritis.
Wang D; Li Y; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
Cantini F; Niccoli L; Goletti D
J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
[TBL] [Abstract][Full Text] [Related]
20. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
Tanaka Y; Hirata S
Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]